

# Neuroblastoma Market - A Global and Regional Analysis: Focus on Treatment and Regional Analysis - Analysis and Forecast, 2025-2035

<https://marketpublishers.com/r/NDBD19DC834FEN.html>

Date: June 2026

Pages: 0

Price: US\$ 4,900.00 (Single User License)

ID: NDBD19DC834FEN

## Abstracts

Neuroblastoma is a rare and aggressive cancer that primarily affects infants and young children, though it can occur in individuals of any age. It arises from immature nerve cells, called neuroblasts, which are typically found in the adrenal glands but can also develop in other areas of the abdomen, chest, neck, or pelvis.

The advancement in treatment options is one of the major driving factors of this market. Immunotherapy, targeted therapies, and radiopharmaceuticals are the treatments used during neuroblastoma treatment. Immunotherapy has significantly improved survival rates for children with high-risk neuroblastoma by using the body's immune system to target cancer cells. The impact here is seen in the reduction of recurrence rates and the improvement of long-term survival, especially in aggressive cases.

One of the significant drivers of the investment in research and development. Government and private investments are accelerating clinical trials for innovative treatments like gene therapies and CAR-T cell therapies. This has the potential to shorten drug development timelines and offer new treatment modalities, enhancing market dynamics and creating new therapeutic classes.

Despite the growth trajectory, several challenges continue to impact the global neuroblastoma market. One of the primary challenges is high treatment costs. The high cost of treatments, especially immunotherapies and biologics, limits access to life-saving therapies, particularly in low-resource settings or for families without adequate insurance. This challenge results in inequities in healthcare access, as many families may be unable to afford these treatments, leading to delays in care or suboptimal treatment choices.

Leading players in the global neuroblastoma market, such as Novartis and Eli Lilly and Company, are continuously innovating to improve the effectiveness and comfort of therapies. These companies are investing heavily in research and development to introduce new, technologically advanced therapies into the market. With a strong emphasis on user-friendly and environmentally sustainable products, these companies are shaping the future of neuroblastoma while enhancing their market positions globally.

The competitive landscape of the global neuroblastoma market is diverse, with numerous players across different regions offering a wide range of products. Regional players and local manufacturers are expected to play an important role in the market's growth, especially as demand increases in emerging markets such as the Asia-Pacific. As consumer preferences shift towards more discreet, comfortable, and affordable solutions, the neuroblastoma market will continue to evolve, fostering new opportunities for both established and emerging companies.

As the neuroblastoma market evolves, emerging trends include a growing focus on pediatric cancer. This trend allows treatments to be more specific and effective for individual patients, reducing side effects and improving patient outcomes.

Hard copy option is available on any of the options above at an additional charge of \$500. Please email us at [order@marketpublishers.com](mailto:order@marketpublishers.com) with your request.

This report will be delivered in 7-10 working days.

## Contents

Executive Summary

Scope of Study

### **1. GLOBAL NEUROBLASTOMA MARKET: MARKET OUTLOOK**

1.1 Industry Outlook

1.1.1 Market Overview and Ecosystem

1.1.2 Market Trends

1.1.3 Epidemiological Analysis of Neuroblastoma

1.1.3.1 By Region

1.1.3.1.1 U.S.

1.1.3.1.2 EU5

1.1.3.1.3 Rest-of-the-World

1.1.4 Clinical Trials

1.1.4.1 By Phase

1.1.4.2 By Sponsor Type

1.1.5 Regulatory Landscape / Compliance

1.1.5.1 Legal Requirement and Framework in the U.S.

1.1.5.2 Legal Requirement and Framework in the E.U.

1.1.5.3 Legal Requirement and Framework in Asia-Pacific

1.1.5.4 Legal Requirement and Framework in Rest-of-the-World

1.2 Market Dynamics

1.2.1 Impact Analysis

1.2.2 Market Drivers

1.2.3 Market Restraints

1.2.4 Market Opportunities

### **2. GLOBAL NEUROBLASTOMA MARKET (BY TREATMENT), \$MILLION, 2024-2035**

2.1 Overview

2.2 Chemotherapy

2.3 Surgery

2.4 Immunotherapy

2.5 Radiation Therapy

2.6 Stem Cell Therapy

### **3. GLOBAL NEUROBLASTOMA MARKET (BY REGION), \$MILLION, 2024-2035**

### 3.1 North America

#### 3.1.1 Key Findings

#### 3.1.2 Market Dynamics

#### 3.1.3 Market Sizing and Forecast

##### 3.1.3.1 North America Neuroblastoma Market (by Country)

###### 3.1.3.1.1 U.S.

###### 3.1.3.1.2 Canada

### 3.2 Europe

#### 3.2.1 Key Findings

#### 3.2.2 Market Dynamics

#### 3.2.3 Market Sizing and Forecast

##### 3.2.3.1 Europe Neuroblastoma Market (by Country)

###### 3.2.3.1.1 U.K.

###### 3.2.3.1.2 Germany

###### 3.2.3.1.3 France

###### 3.2.3.1.4 Italy

###### 3.2.3.1.5 Spain

###### 3.2.3.1.6 Rest-of-Europe

### 3.3 Asia-Pacific

#### 3.3.1 Key Findings

#### 3.3.2 Market Dynamics

#### 3.3.3 Market Sizing and Forecast

##### 3.3.3.1 Asia-Pacific Neuroblastoma Market (by Country)

###### 3.3.3.1.1 Japan

###### 3.3.3.1.2 China

###### 3.3.3.1.3 Rest-of-Asia-Pacific

### 3.4 Rest-of-the-World

#### 3.4.1 Key Findings

#### 3.4.2 Market Dynamics

#### 3.4.3 Market Sizing and Forecast

## **4. GLOBAL NEUROBLASTOMA MARKET - COMPETITIVE BENCHMARKING AND COMPANY PROFILES**

### 4.1 Competitive Landscape

#### 4.1.1 Key Strategies and Developments by Company

##### 4.1.1.1 Funding Activities

##### 4.1.1.2 Mergers and Acquisitions

- 4.1.1.3 Regulatory Approvals
- 4.1.1.4 Partnerships, Collaborations and Business Expansions
- 4.1.2 Key Developments Analysis
- 4.2 Company Profiles
  - 4.2.1 Novartis
    - 4.2.1.1 Company Overview
    - 4.2.1.2 Product Portfolio
    - 4.2.1.3 Target Customers/End Users
    - 4.2.1.4 Analyst View
  - 4.2.2 Clarity Pharmaceuticals
    - 4.2.2.1 Company Overview
    - 4.2.2.2 Product Portfolio
    - 4.2.2.3 Target Customers/End Users
    - 4.2.2.4 Analyst View
  - 4.2.3 Recombio
    - 4.2.3.1 Company Overview
    - 4.2.3.2 Product Portfolio
    - 4.2.3.3 Target Customers/End Users
    - 4.2.3.4 Analyst View
  - 4.2.4 Eli Lilly and Company
    - 4.2.4.1 Company Overview
    - 4.2.4.2 Product Portfolio
    - 4.2.4.3 Target Customers/End Users
    - 4.2.4.4 Analyst View
  - 4.2.5 Y-mAbs Therapeutics
    - 4.2.5.1 Company Overview
    - 4.2.5.2 Product Portfolio
    - 4.2.5.3 Target Customers/End Users
    - 4.2.5.4 Analyst View

## **5. RESEARCH METHODOLOGY**

## List Of Figures

### LIST OF FIGURES

Figure: Neuroblastoma Market (by Scenario), \$Million, 2024, 2030, and 2035

Figure: Global Neuroblastoma Market, 2024 and 2035

Figure: Global Neuroblastoma Market Key Trends, Impact Analysis, 2024-2035

Figure: North America Neuroblastoma Market, \$Million, 2024-2035

Figure: Europe Neuroblastoma Market, \$Million, 2024-2035

Figure: Asia-Pacific Neuroblastoma Market, \$Million, 2024-2035

## List Of Tables

### LIST OF TABLES

Table: Market Snapshot

Table: Global Neuroblastoma Market Dynamics, Impact Analysis

Table: Global Neuroblastoma Market, (by Region), \$Million, 2024-2035

## I would like to order

Product name: Neuroblastoma Market - A Global and Regional Analysis: Focus on Treatment and Regional Analysis - Analysis and Forecast, 2025-2035

Product link: <https://marketpublishers.com/r/NDBD19DC834FEN.html>

Price: US\$ 4,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/NDBD19DC834FEN.html>